Among persons with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide (Mounjaro, Zepbound) reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure and improved sleep-related patient-reported outcomes.